Divya Patel
Internal Medicine · Apple Valley, CANPI 1215591409
Payments from drug & device makers
Across 95 payments — averaging $27.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$320
- Akebia Therapeutics Inc$260
- Bayer$256
- Calliditas Therapeutics US Inc.$204
- Amgen$203
- Ardelyx, Inc.$192
- plus $1K from 16 others
What the payments were for
- Food & beverage$2,55497%
- Education$713%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 11 | $320 |
| Akebia Therapeutics Inc | 11 | $260 |
| Bayer | 7 | $256 |
| Calliditas Therapeutics US Inc. | 6 | $204 |
| Amgen(2 entities) | 5 | $203 |
| Ardelyx, Inc. | 8 | $192 |
| Lilly USA, LLC | 7 | $174 |
| Travere Therapeutics, Inc. | 6 | $153 |
| Boehringer Ingelheim | 5 | $131 |
| ANI Pharmaceuticals, Inc. | 5 | $128 |
| Aurinia Pharma U.S., Inc. | 4 | $112 |
| Otsuka America Pharmaceutical, Inc. | 4 | $104 |
| OPKO Pharmaceuticals, LLC | 4 | $72 |
| Veloxis Pharmaceuticals, Inc. | 1 | $71 |
| Fresenius USA Marketing, Inc. | 2 | $44 |
| AstraZeneca | 2 | $41 |
| Exact Sciences | 2 | $36 |
| GSK | 1 | $32 |
| Novo Nordisk | 1 | $25 |
| Azurity Pharmaceuticals, Inc. | 1 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Cequr Corporation | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,625 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 15 | $13,760 |
| JardianceEmpagliflozin | 19 | $12,611 |
| FarxigaDapagliflozin Propanediol | 14 | $9,531 |
| KerendiaFinerenone | 13 | $9,281 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 12 | $5,706 |
| Diclofenac Sodium | 15 | $4,464 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $2,501 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 26 | $889 |
| Atorvastatin Calcium | 46 | $200 |
| Potassium Chloride | 11 | $194 |
| Tamsulosin Hcl | 16 | $156 |
| Duloxetine Hcl | 16 | $152 |
| Chlorthalidone | 11 | $133 |
| Metformin Hcl | 46 | $130 |
| Losartan Potassium | 38 | $124 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Combivent Respimat | $131 | $18,31731 claims |
| Novo NordiskOzempic | $25 | $13,76015 claims |
| AstraZenecaFarxiga | $41 | $9,53114 claims |
| BayerKerendia | $256 | $9,28113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Apple Valley
- Andrew ChengSouth San Francisco$55.1M
- Joel NeutelTustin$34.9M
- Donald BrandonSan Diego$34M
- William TownerLos Angeles$27.4M
- Rahul AggarwalSan Francisco$24M
- Masoud AzizadNorthridge$21.1M
- Helen StaceyWalnut Creek$20.4M
- Rohit Loombala Jolla$15.1M
- Zeid KayaliColton$14.2M
- Alexandra DrakakiSanta Monica$14.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.